We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: acoramidis
MedXY News
EnglishTag

acoramidis

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Acoramidis Significantly Improves Heart Failure-Related Quality of Life in Transthyretin Amyloid Cardiomyopathy: Insights from the ATTRibute-CM Trial
Cardiologyheart failureacoramidis

Acoramidis Significantly Improves Heart Failure-Related Quality of Life in Transthyretin Amyloid Cardiomyopathy: Insights from the ATTRibute-CM Trial

By MedXY|Aug 4, 2026

Acoramidis demonstrates substantial benefits in heart failure-related health status among ATTR-CM patients, significantly improving patient-reported outcomes and supporting its role in modifying disease trajectory.

Acoramidis and Kidney Function in Transthyretin Amyloid Cardiomyopathy: Clinical Implications and Hemodynamic Insights
Cardiology
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
acoramidis
albuminuria

Acoramidis and Kidney Function in Transthyretin Amyloid Cardiomyopathy: Clinical Implications and Hemodynamic Insights

By MedXY|Jul 3, 2026

Acoramidis stabilizes transthyretin and shows kidney-protective effects in transthyretin amyloid cardiomyopathy by reducing eGFR decline and albuminuria, with an initial reversible dip in kidney function associated with improved clinical ou

Long-Term Durability and Clinical Stability of Acoramidis in Transthyretin Amyloid Cardiomyopathy: A 54-Month Synthesis
CardiologyacoramidisATTR-CM

Long-Term Durability and Clinical Stability of Acoramidis in Transthyretin Amyloid Cardiomyopathy: A 54-Month Synthesis

By MedXY|Apr 2, 2026

This review synthesizes the 54-month results of the ATTRibute-CM open-label extension, demonstrating that early and continuous acoramidis treatment provides sustained reductions in mortality and cardiovascular hospitalizations while maintai

Acoramidis Shows Consistent Benefit in Wild‑Type and Variant Transthyretin Amyloid Cardiomyopathy — Signal Extends Through 42 Months
Cardiologyacoramidistransthyretin amyloid cardiomyopathy

Acoramidis Shows Consistent Benefit in Wild‑Type and Variant Transthyretin Amyloid Cardiomyopathy — Signal Extends Through 42 Months

By MedXY|Nov 18, 2025

In ATTRibute‑CM and its open‑label extension, acoramidis (712 mg twice daily) produced consistent reductions in all‑cause mortality and cardiovascular hospitalizations in both wild‑type and variant ATTR cardiomyopathy, including p.Val142Ile

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities